CHEK1 and familial pancreatic carcinoma: Vice versa, as POLA1 mutations occur in about 7 % of colorectal and pancreatic cancer samples, we additionally used four different ATR and CHK1 inhibitors to assess the chemical inducibility of synthetic lethality in various POLA1-depleted colon and pancreatic cancer cell lines.